Tag Archives: GlaxoSmithKline

Ky. to receive $32M for drug abuse treatment

money and pillsMore than $32 million recovered in settlements with two pharmaceutical companies will be used throughout Kentucky to expand substance abuse treatment, including opiate addictions. The state’s attorney general, Jack Conway, said the settlement funds will help create a new treatment center for adults, treatment scholarships, a grant program for new juvenile treatment beds and/or centers, and expanded services for juveniles.

Kentucky currently only has one-tenth of the substance abuse treatment beds it needs, according to data from the Substance Abuse and Mental Health Services Administration.

Conway’s suit against Merck Sharp & Dohme Corp., which accused the company of failing to disclose to doctors and patients that taking Vioxx significantly raised the risk of heart attack, recently settled for $25 million. His suit against GlaxoSmithKline for failing to disclose that patients taking its diabetes drug, Avandia, were at a higher risk for a cardiovascular event, settled for $15 million.

The illegal use of prescription drugs has dropped among young people in Kentucky over the past four years, according to state officials: in 2008, 15.2% of 12th-graders surveyed said they had used prescription drugs without a doctor’s permission, but that figure dropped to 9% in 2012.

Posted in Informational, Litigation, Pharmaceutical Industry | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment